Galera Therapeutics Inc (GRTX)
0.09
0.00 (0.00%)
USD |
OTCM |
Jun 17, 16:00
Galera Therapeutics Enterprise Value: -8.571M for June 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 17, 2024 | -8.571M |
| June 14, 2024 | -8.353M |
| June 13, 2024 | -8.244M |
| June 12, 2024 | -8.081M |
| June 11, 2024 | -8.043M |
| June 10, 2024 | -8.098M |
| June 07, 2024 | -7.537M |
| June 06, 2024 | -7.347M |
| June 05, 2024 | -7.646M |
| June 04, 2024 | -6.944M |
| June 03, 2024 | -5.579M |
| May 31, 2024 | -1.766M |
| May 30, 2024 | -0.9558M |
| May 29, 2024 | -2.805M |
| May 28, 2024 | -2.37M |
| May 24, 2024 | -2.805M |
| May 23, 2024 | -3.784M |
| May 22, 2024 | -3.371M |
| May 21, 2024 | -3.132M |
| May 20, 2024 | -3.333M |
| May 17, 2024 | -2.805M |
| May 16, 2024 | -2.843M |
| May 15, 2024 | -3.132M |
| May 14, 2024 | -3.942M |
| May 13, 2024 | -3.893M |
| Date | Value |
|---|---|
| May 10, 2024 | -3.888M |
| May 09, 2024 | -3.833M |
| May 08, 2024 | -3.784M |
| May 07, 2024 | -3.898M |
| May 06, 2024 | -4.056M |
| May 03, 2024 | -3.349M |
| May 02, 2024 | -2.936M |
| May 01, 2024 | -3.142M |
| April 30, 2024 | -3.333M |
| April 29, 2024 | -3.534M |
| April 26, 2024 | -3.344M |
| April 25, 2024 | -2.180M |
| April 24, 2024 | -3.528M |
| April 23, 2024 | -2.914M |
| April 22, 2024 | -3.088M |
| April 19, 2024 | -3.458M |
| April 18, 2024 | -3.349M |
| April 17, 2024 | -2.675M |
| April 16, 2024 | -4.219M |
| April 15, 2024 | -5.149M |
| April 12, 2024 | -4.823M |
| April 11, 2024 | -4.758M |
| April 10, 2024 | -4.758M |
| April 09, 2024 | -4.627M |
| April 08, 2024 | -4.703M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-55.13M
Minimum
Dec 02 2021
326.13M
Maximum
Mar 02 2020
72.90M
Average
59.63M
Median
Mar 21 2023
Enterprise Value Benchmarks
| Bio-Path Holdings Inc | 3.770M |
| NovaBay Pharmaceuticals Inc | 3.447M |
| Palatin Technologies Inc | 19.35M |
| iBio Inc | 28.22M |
| Theriva Biologics Inc | -11.03M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.381M |
| Total Expenses (Quarterly) | 4.577M |
| EPS Diluted (Quarterly) | -0.08 |
| Earnings Yield | -1.02K% |